Ketanest-S (Esketamine)

Esketamine works by competitively blocking the NMDA (N‑methyl‑D‑aspartate) receptor, which is a key site for excitatory neurotransmission in the brain. This antagonism reduces neuronal firing, leading to dissociative anesthesia, analgesia, and amnesia. Its high lipophilicity allows quick entry into the central nervous system, producing a rapid onset of effect.

The dose of Ketanest‑S is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and the specific procedure. Dosing regimens are individualized and should follow institutional protocols and the product’s prescribing information. Healthcare professionals are responsible for selecting the appropriate amount.

There is limited clinical data on the use of esketamine during pregnancy or lactation. Because potential risks to the fetus or infant cannot be ruled out, Ketanest‑S should only be used if the expected benefit justifies the potential danger. Consultation with obstetric and neonatal specialists is recommended.

To order Ketanest‑S, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Ketanest‑S contains esketamine, the S‑enantiomer of ketamine, which offers a higher affinity for the NMDA receptor and often provides more potent analgesia with a lower incidence of some side effects compared with racemic ketamine. Compared with propofol or volatile agents, esketamine maintains cardiovascular stability but may produce more psychomimetic effects, requiring careful monitoring.

Ketanest‑S should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility. If the product reaches room temperature, it may be used within the time frame specified in the labeling, after which any remaining solution should be discarded.

Ketanest‑S is administered by a qualified healthcare professional as an intravenous or intramuscular injection. The route, rate of administration, and total dose are individualized according to the clinical situation. Continuous monitoring of vital signs is required throughout the procedure and during the recovery phase.

The most serious risks include respiratory depression, which may necessitate assisted ventilation; laryngospasm, a sudden closure of the airway; and severe neuropsychiatric reactions such as persistent psychosis or extreme agitation. Prompt recognition and immediate supportive measures are essential to mitigate these complications.

Ketanest‑S should be avoided in patients with known hypersensitivity to esketamine or any component of the formulation. Caution is advised in individuals with uncontrolled hypertension, severe cardiovascular disease, elevated intracranial pressure, or a history of psychotic disorders. The drug is also contraindicated in patients where airway protection cannot be guaranteed.